Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors

Pathology Research and Practice

Volumn 194, Issue 9, 1998, Pages 615-621

  Yokoyama, Ryohei ^a,b   Schneider Stock, Regine ^a   Radig, Kathrin ^a   Wex, Thomas ^a   Roessner, Albert ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

MDM2; Oncogene; Osteosarcoma; p53; Ras

Indexed keywords

PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CARCINOGENESIS; CHILD; CLINICAL ARTICLE; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; ONCOGENE K RAS; OSTEOSARCOMA; POINT MUTATION; PROGNOSIS; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE;

EID: 0031689788     PISSN: 03440338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0344-0338(98)80096-4     Document Type: Article

References (33)

1. Antillon-Klüssmann F, Garcia-Delgado M, Villa-Elizaga I, Sierrasesumga L (1995) Mutational activation of ras genes is absent in pediatric osteosarcoma. Cancer Genet Cytogenet 79: 49-53
2. Barrios C, Castresana J, Ruiz J, Kreiebergs A (1993) Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma. J Orthop Res 11: 556-563
3. Belchis DA, Meece CA, Benko FA, Rogan PK, Williams RA, Gocke CD (1996) Loss of heterozygosity and microsatellite instability at the retinoblastoma locus in osteosarcomas. Diag Mol Pathol 5: 214-219
4. Bogenmann E, Moghadam H, Declerck YA, Mock A (1987) c-myc amplification and expression in newly established human osteosarcoma cell lines. Cancer Res 47: 3808-3814
5. Cui LX, Oka T, Dobashi Y, Ishida T, Machinami R (1991) Mutational activation of K-ras gene is absent in human osteosarcoma. Med Sci Res 19: 697-698
6. Dahlin DC, Unni KK (1986) Bone Tumors: General Aspects and Data on 8.542 cases, 4th ed. Charles C. Thomas, Springfield
7. Davis AM, Bell RS, Goodwin PJ (1994) Prognostic factors in osteosarcoma: a critical review. J Clin Oncol 12: 423-431
8. Ebert M, Yokoyama M, Kobrin MS, Friess H, Büchler MW, Korc M (1994) Increased mdm2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. Int J Cancer 5: 1279-1284
9. Feugeas O, Guriec N, Babin-Boilletot A, Marcellin L, Simon R, Babin S, Thyss A, Hofman P, Terrier P, Kalifa C, Brunat-Mentigny M, Patricot LM, Oberling F (1996) Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. J Clin Oncol 14: 467-472
10. Goldman D, Merill CR (1982) Silver staining of DNA in polyacrylamide gels: linearity and effect of fragment size. Electrophoresis 3: 24-26
11. Hesketh R (1995) The Oncogene Factsbook, Academic Press, London
12. Ikeda S, Sumii H, Akiyama K, Watanabe S, Ito S, Inoue H, Takechi H, Tanabe G, Oda T (1989) Amplification of both c-myc and c-raf-1 oncogenes in a human osteosarcoma. Jpn J Cancer Res 80: 6-9
13. Ladanyi M, Cha C, Lewis R, Jhanwar SC, Huvos AG, Healey JH (1993a) MDM2 gene amplification in metastatic osteosarcoma. Cancer Res 53: 16-18
14. Ladanyi M, Park CK, Lewis R, Jhanwar SC, Healey JH, Huvos AG (1993b) Sporadic amplification of the MYC gene in human osteosarcomas. Diagn Mol Pathol 2: 163-167
15. Leach FS, Tokino T, Meltzer P, Burrel M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B (1993) p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 53: 2231-2234
16. Marcove RC, Miké V, Hajek JV, Levin AG, Hutter RVP (1970) Osteogenic sarcoma under the age of twenty-one. J Bone Joint Surg 52-A: 411-423
17. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G (1992) Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 10: 5-15
18. Nakayama T, Toguchida J, Wadayama B, Kanoe H, Kotoura Y, Sasaki M (1995) mdm2 gene amplification in bone and soft tissue tumors: association with tumor progression in differentiated adipose tissue tumors. Int J Cancer 64: 342-346
19. Ohtomo K, Terui S, Yokoyama R, Abe H, Terauchi T; Maeda G, Beppu Y, Fukuma H (1996) Thallium-201 scintigraphy to assess effect of chemotherapy in osteosarcoma. J Nucl Med 37: 1444-1448
20. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358: 80-83
21. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B (1993) Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 362: 857-860
22. Orita M, Suzuki Y, Sekiya T, Hayashi K (1989) Rapid and sensitive detection of point mutations and DNA polymorphism using the polymerase chain reaction. Genomics 5: 874-879
23. Ozaki T, Ikeda S, Kawai A, Inoue H, Oda T (1993) Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue tumors. Cell Mol Biol 39: 235-242
24. Radig K, Schneider-Stock R, Oda Y, Neumann W, Mittler U, Roessner A (1996) Mutation spectrum of p53 gene in highly malignant human osteosarcoma. Gen Diagn Pathol 142: 25-32
25. Salzer-Kuntschik M, Brand G, Delling G (1983) Bestimmung des morphologischen Regressionsgrades nach Chemotherapie bei malignen Knochentumoren. Pathologie 4: 135-141
26. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning. A Laboraty Manual. 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
27. Toguchida J, Ishizaki K, Sasaki MS, Ikenaga M, Sugimoto M, Kotoura Y, Yamamuro T (1988) Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma. Cancer Res 48: 3939-3943
28. Toguchida J, Yamaguchi T, Ritche B, Beauchamp RL, Dayton SH, Herrera GE, Yamamuro T; Kotoura Y, Sasaki MS, Little JB, Weichselbaum RR, Ishizaki K, Yandell DW (1992a) Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res 52: 6194-62199
29. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Weichselbaum RR, Yandell DW (1992b) Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 326: 1301-1308
30. Tomita K, Tsuchiya H (1989) Intermediate results and functional evaluation of limb-salvage surgery for osteosarcoma: an intergroup study in Japan. J Surg Oncol 41: 71-76
31. Unni KK, Dahlin DC (1984) Grading of bone tumors. Semin Diagn Pathol 1: 165-172
32. Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preusser P, Prindull G, Brandeis W, Landbeck G (1988) Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trials (COSS-82) with salvage chemotherapy based on histological response. J Clin Oncol 6: 329-337
33. Yokota J, Tsunetsugu-Yokota Y, Battifora H, Le Fevre C, Cline MJ (1986) Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science 231: 261-265